- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000126
Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
Study Overview
Detailed Description
NAION is the most common cause of acute optic nerve disease in the elderly, causing permanent and severe visual loss. No proven treatment currently exists to reverse or arrest this loss. There is no accepted method for the prevention or reduction of the likelihood of second eye involvement. NAION strikes both eyes in as many as 40 percent of affected patients (Beri et al. 1987), with a 2-year risk of about 25 percent (Steven Feldon, personal communication to SEK).
IONDT compared optic nerve decompression surgery (ONDS), which was becoming a widely used treatment for NAION, with careful followup alone, in patients with newly diagnosed NAION. The rationale for the surgery was that NAION was caused by impaired blood flow to the optic nerve and that decompression surgery would restore vision by alleviating pressure surrounding the nerve. Because ONDS was fast becoming the standard of care, evaluation of the safety and efficacy of the procedure was tested in the context of a randomized clinical trial.
Within 2 years of the start of the IONDT, the Data and Safety Monitoring Committee recommended cessation of the clinical trial recruitment. The National Institutes of Health issued a clinical alert to 25,000 ophthalmologists and neurologists describing the study findings that surgery was no better than careful followup and may be harmful (IONDT 1995). It was recommended that ONDS not be used in cases of NAION. Thus, the IONDT findings not only have led to a costly and ineffective surgery to be abandoned as a treatment for NAION, but also have left practitioners with a dearth of treatment choices.
The IONDT is the first multicenter, prospective study of newly diagnosed patients with NAION. The baseline history and examination, which took place within 14 days of the onset of symptoms, used standardized methods and diagnostic criteria to collect data on all factors possibly relating to the etiology of NAION. In reports from previous studies that present data on both initial and final visual acuities, no data are available regarding change in visual acuity over time for individual patients. Where data are available on final visual acuity, reported rates of improvement are low, ranging from 0 percent to 33 percent for untreated eyes. The IONDT found, however, an improvement of three or more lines in 42.7 percent of patients who received careful followup.
NAION in both eyes has been reported in as few as 10.5 percent and as many as 73 percent of patients. In a study of bilateral NAION where all patients were prospectively logged, Beri et al. reported that 17.5 percent of patients developed bilateral disease at 1 year of followup and 34.5 percent developed it at 5 years. However, Beck et al., using a life table analysis on the same cohort reported by Beri et al., estimated the risk of bilateral NAION to be 12 percent within 2 years and 19 percent within 5 years. The IONDT has so far similarly reported a 12 percent (25/216) incidence of bilateral NAION in its randomized patients. The incidence in the nonrandomized group, 91 percent of whom had visual acuity better than 20/64, is much lower at 4 percent (5/136).
Thus, continued followup of the IONDT cohort is critically important to ascertain a clear picture of the natural history of NAION in terms of involvement of the second eye and long-term vision. Data obtained will be critical in understanding the etiology of the disease and in generating hypotheses for testing further treatments for the disease.
The IONDT Followup Study will continue to monitor vision and other health outcomes in patients originally enrolled in the IONDT, whether randomized to one of the two treatment groups or whether followed as part of the natural history cohort. All IONDT patients were diagnosed with NAION within 14 days of onset of symptoms, have had a minimum of 2 years of continuous followup, and will be followed for an additional 4 years in the Followup Study. Patients will have annual visits at the original IONDT Clinical Center or, if necessary, with a surrogate provider. If NAION occurs in the second eye, the patient will be asked to visit the clinic for a special visit. The Coordinating Center will telephone the patients on a quarterly basis, between annual visits. Outcomes that will be examined include:
- incidence of NAION in the second eye,
- medical or ocular events surrounding the occurrence of NAION,
- visual acuity (measured using the New York Lighthouse charts).
In the event of an NAION event in the second eye, the patient's visual field will be tested by using the Humphrey Perimeter.
Study Type
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States
- Doheny Eye Institute, University of Southern California
-
Los Angeles, California, United States
- Jules Stein Eye Institute
-
San Francisco, California, United States
- Department of Ophthalmology, University of California, San Francisco
-
-
Florida
-
Gainesville, Florida, United States
- Department of Ophthalmology, University of Florida
-
-
Georgia
-
Atlanta, Georgia, United States
- Emory Eye Center, Emory University
-
-
Illinois
-
Chicago, Illinois, United States
- Department of Ophthalmology, University of Illinois
-
-
Kentucky
-
Lexington, Kentucky, United States
- Department of Ophthalmology, University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, United States
- University of Maryland
-
-
Michigan
-
Ann Arbor, Michigan, United States
- W.K. Kellogg Eye Center, University of Michigan
-
East Lansing, Michigan, United States
- Department of Ophthalmology, Michigan State University
-
Royal Oak, Michigan, United States
- William Beaumont Eye Institute, William Beaumont Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States
- Mayo Clinic
-
-
Missouri
-
Columbia, Missouri, United States
- Mason Institute of Ophthalmology, University of Missouri - Columbia
-
St. Louis, Missouri, United States
- St. Louis University, Anheuser-Busch Eye Institute
-
-
New York
-
Syracuse, New York, United States
- SUNY Health Science Center, Department of Neurology
-
-
North Carolina
-
Charlotte, North Carolina, United States
- Carolinas Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States
- The Cleveland Clinic Foundation
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States
- Allegheny General Hospital
-
-
South Carolina
-
Columbia, South Carolina, United States
- University of South Carolina, Department of Ophthalmology
-
-
Texas
-
Houston, Texas, United States
- University of Texas
-
-
Utah
-
Salt Lake City, Utah, United States
- University of Utah, Department of Ophthalmology
-
-
Virginia
-
Charlottesville, Virginia, United States
- University of Virginia, Department of Ophthalmology
-
Richmond, Virginia, United States
- Medical College of Virginia, Department of Neurology
-
-
West Virginia
-
Morgantown, West Virginia, United States
- West Virginia University, Department of Neurology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Other
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEI-25
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Optic Neuropathy
-
Instituto Universitario de Oftalmobiología Aplicada...University of ValladolidActive, not recruitingNon Arteritic Ischemic Optic NeuropathySpain
-
Fraser HealthWithdrawnIschemic Optic Neuropathy | Optic Neuropathy, Ischemic | Anterior Ischemic Optic Neuropathy | Optic Neuropathy, Anterior IschemicCanada
-
Shahid Beheshti University of Medical SciencesUnknownAcute Nonarteritic Anterior Ischemic Optic NeuropathyIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesUnknownNAION( Non-arteritic Anterior Ischemic Optic Neuropathy)Iran, Islamic Republic of
-
Emory UniversityCompletedNon-Arteritic Anterior Ischemic Optic NeuropathyUnited States
-
Shahid Beheshti University of Medical SciencesUnknownNon-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Iran, Islamic Republic of
-
Jeffrey L GoldbergCompletedIschemic Optic Neuropathy/Optic Nerve StrokeUnited States
-
Neuro-Ophthalmologic Associates, PCAcorda TherapeuticsCompletedNon Arteritic Ischemic Optic NeuropathyUnited States
-
Rigshospitalet, DenmarkUniversity of Colorado, Denver; King's College Hospital NHS Trust; Odense University... and other collaboratorsRecruitingNon-arteritic Ischemic Optic Neuropathy | Optic Disk DrusenDenmark, United Kingdom, United States, Australia, Canada, France, Iran, Islamic Republic of, Israel, New Zealand
-
Eli Lilly and CompanyCompletedNonarteritic Anterior Ischemic Optic NeuropathyUnited States
Clinical Trials on Surgery
-
University of AarhusCompletedAcute Post Operative Pain | Chronic Postsurgical PainDenmark
-
International Study Group on Minimally Invasive...Fondazione CARIT; LOGIX S.r.l.Unknown
-
Peking Union Medical College HospitalCompletedPancreatic Neuroendocrine TumorsChina
-
Hospital Central de la Defensa Gómez UllaClinica Universidad de Navarra, Universidad de NavarraEnrolling by invitationRectal Cancer | PROM | Functional Bowel DisorderSpain
-
Sunnybrook Health Sciences CentreMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsCompleted
-
The Second Hospital of Shandong UniversityRecruitingLung Diseases | SurgeryChina
-
Federal University of São PauloUnknownObesity | LymphedemaBrazil
-
Shanghai Zhongshan HospitalUnknownCarcinoma, Pancreatic Ductal | Circulating Tumor CellsChina
-
NHS GrampianBarts & The London NHS Trust; Queen Mary University of London; University of...RecruitingOvarian CancerUnited Kingdom
-
University of BelgradeCompleted